Bayer announces WHO pre-qualification for Fludora® Fusion to combat malaria

• Now fully evaluated by World Health Organisation (WHO) for safety, efficacy and quality.

• First product for indoor residual spraying against malaria vectors to combine two modes of action.

• Addresses the threat of insecticide resistant mosquitoes.

---

 

Monheim/Lyon, December 18, 2018 – The recent WHO Malaria Report 2018 flagged another stalling in the progress towards elimination of the disease, in part due to development of insecticide resistance in vector mosquitoes to current preventative solutions. There is therefore an urgent need to maintain investment into innovation for malaria vector control; to develop new modes of action but also to implement strategies which ensure their sustainability. Fludora® Fusion, the first product of its kind to combine different modes of action, is a prime example of one such strategy.

 

“We are very proud to have achieved WHO Pre-Qualification for Fludora Fusion; it reflects our long-term commitment towards supporting the elimination of vector-borne diseases” explains Dr. Jacqueline M. Applegate, Head of the Environmental Science business unit at Bayer. “It is a clear example of our focus on applying science to advance life – malaria control programs will now have access to an additional safe, efficient and cost-effective solution to protect the millions at risk from the disease.”

 

 

Malaria is a disease which still has a devastating impact on families and communities – particularly in Sub-Saharan Africa. The control of Anopheline mosquitoes with insecticide treated bed-nets and residual insecticides applied inside dwellings is the cornerstone of malaria prevention with 4 in every 5 of the 663 million malaria cases averted between 2000 and 2015 due to the use of such interventions. 

As part of the ongoing investment into vector control product development, over the last four years Bayer has supported field trials with Fludora® Fusion across 15 countries, tested it against more than a dozen resistant mosquito strains, assessed it on more than 20 different surface types and worked with more than a dozen different research institutes in Sub-Saharan Africa.  Data demonstrates that Fludora® Fusion provides robust and consistent results, matching the needs of malaria control programs across Africa. 16 national registration approvals have already been obtained to allow use in these countries.

Emmanuel Hakizimana, Director of the Vector Control Unit at Rwanda Biomedical Center Division of Malaria and Other Parasitic Diseases, reinforces this position: “We have tested Fludora Fusion in our country and seen impressive results. It promises to be a cost-effective solution which will allow us to increase coverage and protect communities for the entire annual malaria transmission period. In addition to various operational benefits, the Fludora Fusion combination approach is a very welcome addition to our choices to tackle resistant mosquitoes and therefore boosts our efforts to reduce malaria in Rwanda.”

 

The UK based Innovative Vector Control Consortium (IVCC) also supported a number of the trials and continues to play an important role partnering with industry in product development to tackle malaria, as well as galvanizing broader advocacy and commitment such as the ‘Zero by 40’ initiative launched in 2018.

 

Nick Hamon, CEO of IVCC, said: “We were happy to have been able to support part of the Fludora Fusion trial program and to see this milestone achieved. New vector control tools are desperately needed to combat resistance and this is another positive addition to the toolbox.”

 

Fludora® Fusion is one important new solution which will contribute to the fight against malaria. In addition, Bayer continues to invest in the development of other tools in order to ensure continued impact against vector-borne diseases and to improve the quality of life of those at risk. 

 

 

About Fludora® Fusion

Fludora™ Fusion is the first product for the Indoor Residual Spraying (IRS) of houses to combine two unrelated modes of action – clothiandin and deltamethrin. The combination approach provides optimum effectiveness against malaria vectors under conditions of insecticide resistance.For more information, please see www.vectorcontrol.bayer.com.

 

About IVCC

IVCC is the only product development partnership (PDP) working in vector control.  Established in 2005, IVCC works with stakeholders to facilitate the development of novel and improved public health insecticides and formulations and provides information tools to enable their effective use. IVCC’s vision is simply to save lives, protect health and increase prosperity by preventing insect-borne diseases. IVCC is funded by The Bill & Melinda Gates Foundation, UKaid, USAID, Unitaid, the Global Fund, the Australian Government and The Swiss Agency for Development and Cooperation.

 

About Bayer

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to www.bayer.com.

 

 

 

Contact:

Utz Klages, Tel. +49 2173 38-3270

E-Mail: utz.klages@bayer.com

 

Diana Scholz, Tel. +33 472854830

E-Mail: diana.scholz@bayer.com

 

kgs                (2018-0384)

 

 

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conformthem to future events or developments.